USA flag logo/image

An Official Website of the United States Government

Safety/Efficacy of Liposomal Reversan, a novel MRP1 modulator for Cancer Therapy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93521
Program Year/Program:
2009 / STTR
Agency Tracking Number:
CA137977
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BUFFALO BIOLABS, LLC
BUFFALO BIOLABS, LLC 73 HIGH ST BUFFALO, NY 14203-1149
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Safety/Efficacy of Liposomal Reversan, a novel MRP1 modulator for Cancer Therapy
Agency: HHS
Contract: 1R41CA137977-01
Award Amount: $104,608.00
 

Abstract:

DESCRIPTION (provided by applicant): One of the major problems in the fight against cancer is the intrinsic or acquired resistance of tumors to current cancer treatments, particularly that associated with multidrug transporters (MDT; e.g. P-glycoprotein (P -gp) and the multidrug associated protein (MRP1)). The clinical failures of early P-gp inhibitors, which either caused non-specific toxicity or pharmacokinetic interactions with conventional chemotherapy agents, has significantly diminished the enthusiasm of pharmaceutical companies to develop MDT inhibitors. Nevertheless, drug resistance associated with these transporters is still a serious problem and the development of inhibitors against these proteins must be revisited using the knowledge and experience gained from previous failures to significantly increase the chances for success. The studies outlined in this proposal center around the optimization of Reversan, a MRP1 inhibitor that surpasses the activity of many known inhibitors of this MDT in the abs ence of toxicity. Our goal is to develop Reversan as an anti-cancer agent to be used together with standard chemotherapy to improve the efficacy of these conventional agents using liposomal formulations of Reversan or Reversan-drug combinations. Liposomal vehicles for in vivo delivery offer important features for tumor delivery of molecules, including decreased systemic clearance rates, decreased systemic toxicity as a result of decreased uptake of formulated agents by normal tissues and at the same time im proved efficacy due to increased uptake of the formulated agents by tumors. The data generated under this proposal will form the basis for the rational design of studies involving other conventional agents as well as for clinical trials using Reversan comb inations to assess the potential of Reversan as an anti-cancer agent. The significance of this project lies in its potential for identifying new treatment strategies for drug refractory cancers, such as neuroblastoma, that are currently faced with limited treatment options due to inherent and acquired drug resistance caused by MRP1 or MDTs in general. PUBLIC HEALTH RELEVANCE: One of the major problems in the fight against cancer is resistance to current cancer treatments, particularly resistance caused by m ultidrug transporters that pump standard cancer drugs out of cancer cells. Inhibitors of these transporters, such as Reversan-the focus of this proposal, when used together with standard chemotherapy should greatly increase the killing of tumor cells by al lowing the drugs to stay in tumor cells. Thus, Reversan has the potential to improve the clinical outcome for patients with limited treatment options due to multidrug resistance.

Principal Investigator:

Arindam Sen
7168458911
ARINDAM.SEN@ROSWLLPARK.ORG

Business Contact:

Linda Webster
lwebster@cbiolabs.com
Small Business Information at Submission:

BUFFALO BIOLABS, LLC
BUFFALO BIOLABS, LLC 73 HIGH ST BUFFALO, NY 14203

EIN/Tax ID: 126472149
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
ROSWELL PARK CANCER INSTITUTE CORP
HEALTH RESEARCH INC. AND ROSWELL PARK CANCER INST
ELM AND CARLTON STREETS
BUFFALO, NY 14263-6203
RI Type: Domestic nonprofit research organization